Outlook Therapeutics Stock (NASDAQ: OTLK)

Outlook Therapeutics (NASDAQ:OTLK) Stock, Quote.Headers.trade-ideas

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Kohl's.Kohls

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

GKOS

OTLK

TOST

This Kohl&#39;s Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Wall Street US stocks

Equities

Eurozone

Commodities

Intraday Update

IREN

UMAC

URBN

Nasdaq Down Over 100 Points; HP Shares Plunge

oil-prices-5079975

Earnings

Dow Falls Over 100 Points; US Crude Oil Stocks Decline

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Citigroup analyst Tyler Radke maintains DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Buy and raises the price target from $87 to $113.

Price Target

DOCU

Citigroup Maintains Buy on DocuSign, Raises Price Target to $113

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and raises the price target from $270 to $380.

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Raises Price Target to $380

DocuSign, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) stock climbed after the company reported better-than-expected third-quarter financial results and issued fourth-quarter and fiscal 2025 revenue guidance above estimates.
On Thursday, DocuSign reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42352653/docusign-stock-soars-on-q3-earnings-beat-revenue-beat-strong-guidance" rel="noreferrer noopener">third-quarter revenue</a> of $754.8 million, up 8%, topping the&nbsp;consensus estimate of $745.26 million. It reported third-quarter adjusted EPS of 90 cents, above analyst estimates of 87 cents.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42368303/whats-going-on-with-us-listed-chinese-stocks-alibaba-jd-nio-li-xpeng-on-friday" rel="noreferrer noopener">What&#8217;s Going On With US Listed Chinese Stocks Alibaba, JD, Nio, Li, XPeng On Friday?</a>
DocuSign forecasts fourth-quarter revenue of $758 million—$762 million, compared to analyst estimates of $755.95 million. 
Wall Street rerated the stock and raised its price targets.
<ul>
<li>RBC Capital analyst Rishi Jaluria maintained DocuSign with a Sector Perform and raised the <a target="_blank" href="https://www.benzinga.com/quote/DOCU/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$57&nbsp;to&nbsp;$90</a>.</li>
<li>Piper Sandler analyst Rob Owens reiterated DocuSign with a Neutral and raised the price target from&nbsp;$60&nbsp;to&nbsp;$90.</li>
<li>JPMorgan analyst Mark R Murphy maintained an Underweight on DocuSign with a price target of $70.</li>
</ul>
RBC Capital: Due to peer multiple expansion, the price target reflects 18x Enterprise Value/Calendar 2025 Free Cash Flow from the prior 11x.&nbsp;&nbsp;
DocuSign reported a good beat-and-raise quarter, leading to an after-hours stock rally. Billings acceleration highlighted the quarter. One-third of billings came from early renewals, but usage trends are increasing. 
The company raised its guidance well ahead of outperformance, and NRR improved. While there was improvement in the core business, the case for meaningful acceleration rests on ramping up Intelligent Agreement Management (IAM), which remains early.
Jaluria noted most of the outperformance coming from results in the third quarter as more of a function of the demand environment stabilizing. He wants to see more proof points regarding IAM adoption to get comfortable underwriting acceleration. 
Operating margin expansion was impressive, but the upside is becoming more muted. Jaluria expects this trend to continue into fiscal 2026 as management strives to accelerate growth back to double-digits. Overall, the quarter was solid, but clarity into IAM driving a sustained growth acceleration still needs improvement.
Jaluria projects fourth-quarter revenue of $760.2 million and EPS of $0.83.
Piper Sandler: The third-quarter top- and bottom-line metrics came in above expectations, with billings growth showing upside on an easy comp, driven partly by early quarterly renewals. IAM showed strength in its first full quarter, with ~80% of sales representatives closing three or more IAM deals. 
While Owens is encouraged by the acceleration, he noted it is still too early until newer products and solutions contribute meaningfully to the model &#8211; and overall growth. The analyst awaits durable signs of inflection from newer growth levers.
Owens projects fourth-quarter revenue of $760 million and EPS of $0.87.
JP Morgan: In Murphy&#8217;s preview, he expressed a positive tone heading into DocuSign&#8217;s third-quarter results while raising his price target, calling out the likelihood for positive early indications on newer product initiatives such as IAM, improvements in transactional activity including envelope and consumption patterns, and further operational refinements to the business that could support a pick-up in underlying organic growth trends. 
Overall, Murphy noted this aligns well with DocuSign results as it posts a mild uptick in third-quarter revenue growth and billings growth, which is picking up more noticeably off a very depressed second-quarter level alongside positive demand commentary. 
As a reminder, across his recent notes, he had explicitly called out DocuSign as among a group of beaten down, pandemic pull-forward stocks that could see positive share price reactions if they deliver growth rates that are stabilizing or picking up, which has primarily played out across this group, including for Twilio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) and Zoom Communications, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) in recent months. 
Overall, Murphy remains complimentary of DocuSign&#8217;s turnaround execution and innovation efforts. However, it remains focused on a more straightforward path to recapturing sustainable, long-term double-digit growth, reiterating it as an aspirational target today, alongside a cleaner GAAP profitability framework to provide further valuation support that SBC doesn&#8217;t inflate.
While acknowledging a moderation in the pace of revenue deceleration, Murphy noted the risk/reward dynamic for DocuSign shares as inferior relative to our broader software coverage list, with revenue and billings growth continuing to show muted growth. 
The analyst noted it would take time for the company&#8217;s investments in self-serve motion and product innovation to bear fruit and regain investor confidence in its long-term ability to drive higher ARPU and steady new customer wins, particularly among large enterprises.
Murphy projects fourth-quarter revenue of $760.0 million and EPS of $0.85.
Price Action: DOCU stock is up 28% at $107.00 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42369000/booz-allen-and-palantir-partner-to-drive-us-defense-operations" target="_blank" rel="noreferrer noopener">Booz Allen and Palantir Partner To Drive US Defense Operations</a></li>
</ul>
Photo: Shutterstock

Reiteration

TWLO

DocuSign Stock Jumps On Strong Q3, Analysts Await Proof Of Sustained Growth

Citigroup analyst Kelly Crago maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and raises the price target from $390 to $450.

ULTA

Citigroup Maintains Neutral on Ulta Beauty, Raises Price Target to $450

Citigroup analyst Paul Diamond maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $33 to $38.

Citigroup Maintains Neutral on Range Resources, Raises Price Target to $38

Citigroup analyst Scott Gruber maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and raises the price target from $145 to $163.

Citigroup Maintains Neutral on Hess, Raises Price Target to $163

Citigroup analyst Paul Diamond maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and raises the price target from $100 to $115.

Citigroup Maintains Buy on Expand Energy, Raises Price Target to $115

As financial markets adjust to new economic and political realities, investors can sharpen their trading skills with a special virtual event by Benzinga.
&#8220;Trading the New Trump Era: Leveraged ETF Bets for a Changing Economy&#8221; <a href="https://www.benzinga.com/events/direxion-dec-12-2024/">will take place</a> on Thursday, Dec. 12, 2024, at 11 a.m. EST and will offer a comprehensive look at the mechanics and strategies behind leveraged ETFs.
This live 90-minute boot camp features seasoned analysts from Direxion, a leader in leveraged ETFs, and Mercator LLC, a firm known for its in-depth research on global financial trends. The event aims to equip attendees with practical tools to understand and trade these specialized financial products.
<h1 class="wp-block-heading">Practical Knowledge From Industry Experts</h1>
Eliott Wellenbach, senior vice president and institutional ETF strategist at Direxion, will lead a discussion on the effective use of leveraged ETFs in active trading. These funds allow investors to amplify their exposure to market movements —bullish or bearish — over a single trading day.
The company emphasizes that these products are not meant for long-term investments but for those who actively monitor and adjust their portfolios. 
Gianni Di Poce, an analyst at Mercator LLC, will join Wellenbach. With over 12 years of experience in financial markets across the U.S. and Europe, Di Poce brings a global viewpoint to the discussion, helping participants understand the factors shaping markets and how leveraged ETFs respond to them.
<h1 class="wp-block-heading">Interactive and Case-Based Learning</h1>
The session promises an immersive experience, featuring live case studies that showcase real-world scenarios where leveraged ETFs can be effectively applied. Attendees can also engage directly with the speakers by asking questions in real time, making the event interactive and focused on practical applications.
This virtual boot camp is designed for traders looking to refine their methods and better understand products that can respond to rapidly shifting markets. Direxion's offerings are particularly suited for those who trade frequently and seek to benefit from market volatility.
Mercator LLC adds depth by offering a macroeconomic analysis that helps traders identify patterns and opportunities in global financial systems.
<h1 class="wp-block-heading">Register for a Tactical Trading Session</h1>
The event represents an opportunity for experienced investors to learn from professionals who specialize in leveraging market opportunities.<a href="https://www.benzinga.com/events/direxion-dec-12-2024/"> Benzinga's boot camp promises</a> an engaging and informative session for those ready to dive into the complexities of leveraged ETFs with guidance from industry leaders.
Read Next: <a href="https://www.benzinga.com/24/12/42352997/santa-rally-here-are-10-sp-500-stocks-that-historically-outperformed-in-decembers-second-half"> • Santa Rally: 10 S&amp;P 500 Stocks That Outperform In December&#8217;s Second Half</a>
Photo: Pexels

Events

Exclusives

ETFs

Leveraged ETFs In Focus: Benzinga Hosts Virtual Boot Camp On Trading Strategies

In the current market session, WEX Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) share price is at $183.45, after a 0.41% spike. Moreover, over the past month, the stock fell by 0.69%, but in the past year, went up by 1.07%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1733514347_0.png" alt="Past Year Chart" />

<h3>WEX P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
WEX has a lower P/E than the aggregate P/E of 40.95 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733514347_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

P/E Ratio Insights for WEX

Canada&#8217;s dried flower exports have seen impressive growth, doubling year-over-year in 3Q24, with the sector hitting record levels in October. According to Pablo Zuanic, senior analyst at Zuanic &amp; Associates, &#8220;The strong growth in dried flower exports signals a thriving international market, with Germany emerging as a key driver.&#8221;
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Record-Breaking October And Strong 3Q Growth</h3>
In October 2024, Canadian dried flower exports reached an all-time high of $20.18 million, positioning Canada's export market to surpass $187.5 million by the end of 2024, compared to $120 million in 2023 and $96 million in 2022.
For 3Q24, exports totaled C$69 million, a 106% year-over-year increase and a 19% quarter-over-quarter rise. Zuanic forecasts that Q4 2024 will see further growth, potentially reaching C$85 million, a year-over-year jump of 87%.
<h3 class="wp-block-heading">Germany And Australia Lead Export Growth</h3>
While Australia remains the largest importer of Canadian dried flowers, Germany is rapidly gaining ground.&nbsp;
In 3Q24, Germany accounted for 26% of total Canadian dried flower exports, a significant increase from 28% in the previous year. Notably, <a href="https://www.benzinga.com/topic/germany-cannabis">sales to Germany</a>, including reshipments from Portugal, were responsible for about half of the export growth during the quarter.<a href="https://zuanicgroup.com/"> Zuanic points out</a>, "Germany's stock-outs and tight inventories reflect ongoing demand, suggesting strong growth ahead for the market.&#8221;
Average export prices for dried flowers in 3Q24 stood at $1.58 per gram, a decrease from $1.67 per gram in Q2 but up from $1.46 per gram in Q3 2023. Export prices to Germany were notably higher at $2.55 per gram, up from $2.39 per gram in Q2, highlighting the lucrative nature of the<a href="https://www.benzinga.com/markets/cannabis/24/10/41382195/german-medical-marijuana-sales-to-reach-1-09b-by-2028-new-report"> German market</a>.
Zuanic also highlighted the performance of key players in the export space. "Aurora&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) exports come entirely from Canada, while Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) ships from Canada to Portugal for EU GMP processing," he noted. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna">Europe Is Turning Cash Flow Positive, &#8216;We&#8217;ll See What Happens In The U.S.,&#8217; Says Curaleaf&#8217;s Boris Jordan</a>
<h3 class="wp-block-heading">Extracts Market Shows Less Consistent Growth</h3>
While dried flower exports have flourished, the growth of<a href="https://www.benzinga.com/topic/canada-cannabis"> Canada&#8217;s cannabis extracts</a>, including <a href="https://www.benzinga.com/topic/cannabis-vaping">oils and vapes</a>, has been more erratic. Exports of extracts totaled $32.02 million for the first nine months of 2024, down from $41.7 million in the same period of 2023.
Notably, flower exports now vastly outpace extracts.&nbsp;
In 2023, flower exports were more than twice the value of extracts, but by 3Q24, dried flower exports were nearly six times the size of extracts. <a href="https://zuanicgroup.com/">Zuanic</a> explains, "As medical cannabis markets deregulate, dried flower exports are likely to continue driving overall growth, especially in Germany.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39442869/2-9b-european-cannabis-market-a-strategic-blueprint-for-cross-border-transportation-logistics">$2.9B European Cannabis Market: A Strategic Blueprint For Cross-Border Transportation Logistics</a>
<h3 class="wp-block-heading">Down The Commodity Lane </h3>
What does <a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic's analysis</a> teach other markets? We could argue that while<a href="https://www.benzinga.com/topic/canada-cannabis"> Canada</a> leads in cannabis exports, it remains heavily reliant on the commoditization of raw flowers, which risks the deterioration of exchange terms over time, especially as European countries begin to extract oil locally rather than purchasing Canadian cannabis oil.&nbsp;
Emerging cannabis economies like <a href="https://www.benzinga.com/topic/colombia-cannabis">Colombia</a>, <a href="https://www.benzinga.com/topic/argentina-cannabis">Argentina</a>, and <a href="https://www.benzinga.com/topic/south-africa-cannabis">South Africa</a> must avoid this trap by investing in value-added industries such as oils, extracts, and vapes, to ensure they aren't relegated to supplying just raw materials.&nbsp;
By focusing on developing local processing and product innovation, they can capture a larger share of the global cannabis value chain and secure more sustainable, profitable growth in the future.
Read Next: <a href="https://www.benzinga.com/general/market-summary/24/11/42126680/german-cannabis-20-tons-10m-grams-and-thats-only-0-3-of-the-market-whats-missing">German Cannabis: 20 Tons, 10M Grams &#8211; And That&#8217;s Only 0.3% Of The Market, What&#8217;s Missing?</a>

Analyst Color

Cannabis

Market Summary

Mid Cap

Emerging Markets

Contracts

Retail Sales

Management

Global

Success Stories

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Europe Says Thanks But We'll Do It Ourselves - Canada Leads In Raw Cannabis Exports, Not Oil

Citigroup analyst Scott Gruber maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Buy and raises the price target from $44 to $51.

Citigroup Maintains Buy on EQT, Raises Price Target to $51

Ubisoft Entertainment SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UBSFF#OTC">UBSFF</a>) is in talks with Tencent Holdings ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) over a potential buyout.
According to Reuters, the deal would allow Ubisoft&#8217;s founders, the Guillemot family, to retain control if the company goes private.
This development follows a <a href="https://www.benzinga.com/general/gaming/24/09/40801168/ubisoft-is-mismanaged-shareholders-are-hostages-investor-demands-video-game-company-go-private-aft">difficult year for Ubisoft</a>, marked by staff layoffs, disappointing sales, and the closure of several studios. Ubisoft&#8217;s stock jumped 14% after news of the buyout discussions emerged, as per <a href="https://pro.benzinga.com/dashboard">BZPro.</a>
See Also: <a href="https://www.benzinga.com/24/12/42366954/neteases-marvel-rivals-launches-with-444000-players-on-steam">NetEase&#8217;s Marvel Rivals Launches With 444,000 Players On Steam</a>
<h3 class="wp-block-heading">Privatization Could Mean Big Changes For Ubisoft</h3>
Sources have told Reuters that Ubisoft is exploring a deal that would allow it to buy back shares from public shareholders, essentially taking the company off the stock market. 
While the Guillemot family wants to maintain control, Tencent's <a href="https://www.benzinga.com/general/24/10/41356456/tencent-may-join-forces-for-ubisoft-bid">significant stake in the company</a> means it will likely demand a larger say in future business decisions.
&#8220;We remain committed to making decisions in the best interests of all of our stakeholders,&#8221; a spokesperson for Ubisoft told Eurogamer. &#8220;In this context, as we have already indicated, the Company is also reviewing all its strategic options.&#8221;
<h3 class="wp-block-heading">Struggling With Financial Losses</h3>
The buyout discussions come amid tough financial times for Ubisoft. The company has faced layoffs, staff walkouts, and a series of underperforming game releases. <a href="https://www.benzinga.com/general/gaming/24/09/40717689/star-wars-outlaws-sales-slump-ubisoft-shares-hit-near-10-year-low">Star Wars Outlaws sold below expectations</a>, and Assassin&#8217;s Creed Shadows, one of Ubisoft's flagship titles, has been delayed until February 2025.
Earlier this week, Ubisoft announced it would close several studios, cutting 277 jobs, while <a href="https://www.benzinga.com/24/12/42320697/277-jobs-cut-as-ubisoft-ends-xdefiant-development">pulling the plug on the live-service shooter XDefiant. </a>
<h3 class="wp-block-heading">Tencent's Growing Influence</h3>
Tencent, already the second-largest shareholder of Ubisoft, has been increasingly active in the gaming industry, having acquired stakes in major companies such as Epic Games and <a href="https://www.benzinga.com/general/social-media/24/12/42275520/riot-games-expands-creator-rules-off-platform-misconduct-faces-penalties">Riot Games. </a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/12/42305217/gamers-now-watch-more-than-they-play-how-publishers-can-reclaim-lost-revenue-report">Gamers Now Watch More Than They Play — How Publishers Can Reclaim Lost Revenue: Report</a></li>
</ul>
Image made with photos from Shutterstock.

Gaming

General

TCEHY

UBSFF

Ubisoft Stock Jumps 14% After Reports Of Tencent Buyout

Citigroup analyst Paul Diamond maintains Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) with a Neutral and raises the price target from $12.5 to $15.5.

Citigroup Maintains Neutral on Comstock Resources, Raises Price Target to $15.5

Citigroup analyst Paul Diamond maintains Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) with a Neutral and raises the price target from $29 to $35.

Citigroup Maintains Neutral on Antero Resources, Raises Price Target to $35

Shares of D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) are trading higher Friday following recent developments across the quantum computing sector, driven in part by announcements from major companies and growing recognition of quantum computing&#8217;s potential economic impact. Here&#8217;s <a href="https://www.benzinga.com/quote/QBTS/news">what you need to know.</a>
What To Know: On Monday, D-Wave participated in the Quantum Technologies Forum at the University of Southern California (USC). During the event, D-Wave highlighted advancements in its annealing quantum computing technology and presented practical use cases from commercial and research clients. Notably, USC hosts a D-Wave Advantage quantum system, emphasizing the company&#8217;s foothold in both academic and enterprise applications.
Earlier this week, D-Wave also announced plans to feature its solutions at the upcoming Q2B24 Silicon Valley conference. The presentation will focus on the application of quantum optimization for business challenges such as workforce scheduling, network resource allocation and manufacturing processes. Company representatives stated that its annealing quantum systems provide measurable benefits in these areas, including reduced scheduling times and improved resource utilization.
The broader quantum computing industry has seen increased activity. Analysts project the global enterprise quantum computing market will grow at a compound annual rate of 29.7%, reaching $10.83 billion by 2028. This growth aligns with forecasts suggesting quantum computing could generate a $1 trillion economic impact by 2035.
In the financial community, D-Wave&#8217;s CEO, Dr. Alan Baratz, recently appeared on Fox Business to discuss the company&#8217;s advancements and the growing commercial adoption of its quantum technology. Baratz emphasized the company&#8217;s role as a leader in delivering quantum solutions for operational use cases, reinforcing its position in the market.
QBTS Price Action: D-Wave Quantum shares were up 32.0% at $4.98 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06140007/QBTS-1024x525.png" alt="" class="wp-image-681193" style="width:448px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06140007/QBTS-1024x525.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06140007/QBTS-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06140007/QBTS-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/06140007/QBTS.png 1488w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42371072/whats-going-on-with-rocket-lab-stock-today">What&#8217;s Going On With Rocket Lab Stock on Friday?</a></li>
</ul>
Image Via Shutterstock.

Movers

QBTS

D-Wave Quantum Shares Are Up Today: What's Going On?

<a href="https://www.youtube.com/watch?v=QkRuAm1hBE4">https://www.youtube.com/watch?v=QkRuAm1hBE4</a>
&nbsp;

Rumors

NMRA

Watching Neumora Therapeutics; Shares See Volume To The Upside, Traders Circulate Unconfirmed Analyst Comments Saying "We Remain Buyers Into NMRA's MDD Data, Citing JNJ's Early Completion Of Phase III Aticaprant Study Efficacy And Safety Profile, Suggesting Potential Readthroughs To NMRA's Upcoming KOASTAL-1 Phase III Data, Expected Within Weeks"

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) shares <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">are trading higher Friday</a> after the company reported third-quarter adjusted earnings per share of 89 cents, <a href="https://www.benzinga.com/news/earnings/24/12/42341098/dollar-general-clocks-upbeat-q3-same-store-sales-despite-hurricanes-and-financially-constrained-core-customers-tightens-annual-outlook" target="_blank" rel="noreferrer noopener">missing the consensus of 94 cents.</a>
The discount retailer&#8217;s EPS is down 29.4% year-over-year. It now expects 2024 net sales growth of approximately 4.8% to 5.1%, compared to its previous expectation of <a href="https://www.benzinga.com/news/earnings/24/08/40623595/dollar-general-q2-earnings-earnings-miss-slashed-outlook-and-shrinking-margins" target="_blank" rel="noreferrer noopener">roughly 4.7% to 5.3%</a>.
Here are the analysts&#8217; takes on the&nbsp;earnings results:
<ul>
<li>Goldman Sachs analyst Kate McShane reiterated the Buy rating, lowering the price objective to $104 from $122.</li>
<li>Bank of America Securities analyst Robert F. Ohmes upgraded Dollar General from Underperform to Buy, with a price forecast of $95.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" rel="noreferrer noopener">TikTok Loses Court Appeal Against Ban, Meta, Reddit Stocks Hit All-Time High</a>
McShane raised the fiscal year 2024 EPS estimate by 0.9% to $5.79. This reflects lower interest expenses from paying down a $750 million note.
The fiscal year 2025 and fiscal 2026 EPS estimates were lowered by 6.8% and 7.4%, respectively. This was due to higher SG&amp;A growth and expected return of incentive compensation.
Overall, the analyst notes that Dollar General saw small wins this quarter, including positive traffic, monthly comps, larger basket sizes, discretionary growth, and share gains with higher-income consumers.
Ohmes upgraded the stock, citing early success in its &#8220;Back-to-Basics&#8221; strategy, including improved inventory, higher in-stock levels, better customer satisfaction, and strong merchandising.
Ohmes also noted SKU reductions, a refreshed sorting process, and the launch of e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) products as factors supporting growth and profitability in 2025.
The analyst sees benefits from inventory rightsizing, with overall and NC inventory down 7% and 9% per store, respectively, along with plans for 2K full store and 2.25K &#8220;Project Elevate&#8221; remodels, supporting comps of 6%-8% and 3%-5%, respectively.
Price Action: DG shares are trading higher by 2.93% to $81.96&nbsp; at last check Friday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42363171/uber-and-weride-come-together-to-launch-robotaxi-service-in-abu-dhabi" target="_blank" rel="noreferrer noopener">Uber And WeRide Partner For Robotaxi Service In Abu Dhabi</a></li>
</ul>
Image: Shutterstock

Dollar General 'Back-To-Basics' Strategy Earns Analyst Upgrade Following Mixed Earnings

Needham analyst Gerald Pascarelli initiated coverage on Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Buy rating and <a target="_blank" href="https://www.benzinga.com/quote/CELH/analyst-ratings" rel="noreferrer noopener">a price target of $38</a>.
The analyst says that as the third-largest player in energy drinks, CELH is positioned to benefit from a healthier category rebound and growing demand for zero-sugar products, creating a favorable environment for revenue acceleration alongside easier year-over-year comparisons.
The analyst writes that while the company recently saw its first year-over-year share loss, they are encouraged by the category&#8217;s return to a high single-digit growth rate.
If this trend continues, CELH stands to benefit from a healthier market backdrop, easier comps, and upcoming innovations planned for 2025, adds the analyst.
Additionally, inventory optimization challenges appear to be resolving, which should improve alignment between sell-through and reported results.
The analyst estimates full year 2024 revenue and EPS of $1.365 billion and $0.68 and $1.548 billion and $0.93 in fiscal year 2025, respectively.
Last month, the company reported third-quarter earnings per share of $0.00, missing the street view of $0.04. Quarterly sales of $265.70 million (down 31%) missed <a href="https://www.benzinga.com/news/earnings/24/11/41773974/energy-drink-maker-celsius-misses-on-q3-earnings-as-supply-chain-optimization-weighs-on-margins-det" target="_blank" rel="noreferrer noopener">the analyst consensus of $267.11 million</a>.
<h2 class="wp-block-heading">Is Celsius Holdings A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/CELH">Celsius Holdings</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Celsius Holdings does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 14.2%, you'll need to buy a share of Ellington Residential by the Dec. 31, 2024. Once done, you can expect to receive a nominal payout of $0.08 on Jan. 27, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/CELH">Celsius Holdings</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
Price Action: CELH shares are up 0.17% at $27.94 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42366105" target="_blank" rel="noreferrer noopener">Chevron Eyes $15.5 Billion Capex for 2025, Anticipates Upto $1.5 Billion Charges In Q4</a></li>
</ul>
Photo via Shutterstock

Large Cap

Initiation

CELH

Energy Drink Firm Celsius Set to Energize Market Growth, Analyst Sees Significant Upside

Citigroup analyst Fatima Boolani maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $48 to $75.

RBRK

Citigroup Maintains Buy on Rubrik, Raises Price Target to $75

Investors with a lot of money to spend have taken a bullish stance on DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DOCU, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 41 uncommon options trades for DocuSign.
This isn't normal.
The overall sentiment of these big-money traders is split between 68% bullish and 24%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $145,190, and 37 are calls, for a total amount of $2,062,390.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $120.0 for DocuSign, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DocuSign's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DocuSign's whale trades within a strike price range from $55.0 to $120.0 in the last 30 days. 
<h3>DocuSign 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733513458_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.0</td>
<td>$8.0</td>
<td>$9.0</td>
<td>$90.00</td>
<td>$315.0K</td>
<td>2.7K</td>
<td align="right">356</td>
</tr>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.25</td>
<td>$5.05</td>
<td>$5.2</td>
<td>$105.00</td>
<td>$129.4K</td>
<td>479</td>
<td align="right">948</td>
</tr>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.25</td>
<td>$5.05</td>
<td>$5.2</td>
<td>$105.00</td>
<td>$105.0K</td>
<td>479</td>
<td align="right">699</td>
</tr>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.11</td>
<td>$2.0</td>
<td>$2.1</td>
<td>$110.00</td>
<td>$104.5K</td>
<td>23</td>
<td align="right">798</td>
</tr>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.5</td>
<td>$13.75</td>
<td>$15.0</td>
<td>$85.00</td>
<td>$75.0K</td>
<td>2.7K</td>
<td align="right">76</td>
</tr>
</tbody>
</table>

<h3>About DocuSign</h3>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in May 2018.
In light of the recent options history for DocuSign, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of DocuSign</h3>
<ul>
<li>With a trading volume of 14,101,936, the price of DOCU is up by 26.51%, reaching $105.86.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DocuSign options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Unpacking the Latest Options Trading Trends in DocuSign

Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical trials ev...

Outlook Therapeutics reports preliminary results from Norse Eight trials

Outlook plunges as lead asset fails in wet AMD study

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IN8bio (INAB – Research Report), Vigil Neuroscience ...

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)

VCI Global Limited, T Stamp Inc., and Outlook Therapeutics are the 3&nbsp;Penny Stocks&nbsp;to watch on November 29, 2024, based on&nbsp;TipRanks' ...

3 Penny Stocks to Watch Now, 11/29/24

BTIG lowered the firm's price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did...

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

Unusual total active option classes on open include: Kellogg (K), Outlook Therapeutics Inc (OTLK), Regions Financial (RF), Applied Therapeutics (AP...

Unusually active option classes on open November 29th

Chardan analyst Daniil Gataulin downgraded Outlook Therapeutics (OTLK) to Neutral from Buy without a price target after the company reported prelim...

Outlook Therapeutics downgraded to Neutral from Buy at Chardan

Outlook Therapeutics (OTLK) announced that Russell Trenary has stepped down as the company's president and CEO, effective immediately. Lawrence Ken...

Outlook Therapeutics CEO Russell Trenary steps down

Outlook Therapeutics announces CEO resignation

An announcement from Outlook Therapeutics ( ($OTLK) ) is now available. On December 3, 2024, C. Russell Trenary III resigned as CEO of Outlook Ther...

Outlook Therapeutics Appoints Interim CEO After CEO Resignation

APLT

DELL

FSLR

IDAI

INAB

SOXS

VCIG

VIGL

Press Releases

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Legal

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Outlook Therapeutics

Outlook Therapeutics (OTLK) Forecast

Outlook Therapeutics (NASDAQ:OTLK) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga